Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yanni Souroutzidis
CANT
Yanni Souroutzidis
Cantor Fitzgerald
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-31.0%
Average Return
0 of 2 calls profitable · -44.0% vs benchmark
📈 Across the calls we could measure, roughly 0% of Yanni Souroutzidis's ratings turned a profit when each position was held for 2 year — averaging -31.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

4 Buy 0 Hold 0 Sell
Yanni's Stock Coverage 3 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
TRDA
Entrada Therapeutics Inc
 Apr 01, 2026 BUY Strong Buy
+198.5% avg upside
10 analysts
 — -49.5%
TSE:MSCL
Satellos Bioscience
 Mar 11, 2026 BUY Strong Buy
+281.4% avg upside
6 analysts
 — ·
KPTI
Karyopharm Therapeutics
 Mar 06, 2026 BUY Strong Buy
+147.4% avg upside
18 analysts
 — -12.5%
Yanni Souroutzidis — Frequently Asked Questions
How accurate are Yanni Souroutzidis's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Yanni's ratings were profitable over a one-year hold, with an average return of -31.0% per rating, or -44.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Yanni ranked on 13Foresight?
Yanni Souroutzidis is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yanni cover?
Yanni most recently has ratings on TRDA, TSE:MSCL, KPTI. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.